{
  "question_stem": {
    "en": "A 48-year-old man comes to the office for a follow-up visit. He was diagnosed with hypercholesterolemia 6 months ago and has been strictly following dietary and lifestyle modifications as advised. The patient has no other medical problems. He does not use tobacco, alcohol, or illicit drugs. His father has diabetes mellitus and coronary artery disease. The patient's blood pressure is 126/70 mm Hg and BMI is 33.1 kg/m². Physical examination is normal. Laboratory studies show a current LDL level of 190 mg/dL. ",
    "zh": "一名48岁的男性前来复诊。6个月前他被诊断为高胆固醇血症，并且一直严格遵循医嘱进行饮食和生活方式的调整。患者没有其他医学问题。他不使用烟草、酒精或违禁药物。他的父亲患有糖尿病和冠心病。患者的血压为126/70 mm Hg，BMI为33.1 kg/m²。体格检查正常。实验室检查显示目前的LDL水平为190 mg/dL。"
  },
  "question": {
    "en": "Which of the following should be obtained before starting statin therapy in this patient?",
    "zh": "在该患者开始他汀类药物治疗之前，应获取以下哪一项？"
  },
  "options": {
    "A": {
      "en": "Apolipoprotein-B level",
      "zh": "载脂蛋白B水平"
    },
    "B": {
      "en": "Complete blood count",
      "zh": "全血细胞计数"
    },
    "C": {
      "en": "Lipoprotein lipase activity assay",
      "zh": "脂蛋白脂酶活性测定"
    },
    "D": {
      "en": "Liver transaminase levels",
      "zh": "肝转氨酶水平"
    },
    "E": {
      "en": "Serum cortisol level",
      "zh": "血清皮质醇水平"
    },
    "F": {
      "en": "Serum creatinine",
      "zh": "血清肌酐"
    }
  },
  "correct_answer": "D",
  "explanation": {
    "en": "This patient has a severe elevation in his LDL level. This degree of hyperlipidemia, especially with a family history of coronary artery disease, suggests familial hypercholesterolemia and confers a very high risk for cardiovascular events. HMG-CoA reductase inhibitors (statins) are the first-line therapy for most patients with hypercholesterolemia and have been proven to reduce the risk of cardiac events. The statins are structural analogs of HMG-CoA and competitively inhibit HMG-CoA reductase, the enzyme responsible for the rate-limiting step in cholesterol synthesis.\n\nSerious side effects of statins include myopathy and hepatitis. Although mild elevations of liver enzymes are common, significant liver injury (aspartate transaminase/alanine transaminase levels more than 3 times the upper limit of normal) is seen in less than 1% of patients and is usually reversible if the medication is discontinued. Liver function tests are recommended before starting statin therapy; otherwise, routine monitoring is not necessary unless symptoms of hepatic injury develop (eg, fatigue, malaise, anorexia).\n\n(Choice A) Apolipoprotein-B (Apo-B) is a structural protein found in atherogenic lipoprotein particles. Each lipoprotein particle contains only a single Apo-B molecule, so measurement of Apo-B levels can quantify the LDL particle count. Patients with increased LDL particle counts are at greater risk for cardiovascular events. However, measurement is of limited clinical utility and would not change management in this case.\n\n(Choice B) Statin medications do not cause any significant hematologic toxicity.\n\n(Choice C) Lipoprotein lipase deficiency can cause familial hypertriglyceridemia (heterozygous deficiency) and chylomicronemia (homozygous deficiency) syndromes. These conditions present with elevated serum triglyceride levels but do not cause elevation in LDL levels.\n\n(Choice E) Because cholesterol is a precursor in the synthesis of adrenocortical and gonadal steroid hormones, statin medications can, in theory, cause hypogonadism or hypoadrenalism. Clinically, however, there are no significant alterations in serum cortisol or gonadal steroid levels unless patients are also on other adrenal enzyme inhibitors (eg, ketoconazole, aminoglutethimide).\n\n(Choice F) Statins have no significant renal side effects. In rare instances, they can cause rhabdomyolysis, which can precipitate acute renal failure; however, this occurs less commonly than hepatic dysfunction and would be associated with myalgias and myoglobinuria.\n\nEducational objective:\nCommon side effects of HMG-CoA reductase inhibitors (statins) include muscle and liver toxicity. Hepatic transaminases should be checked prior to initiating therapy and repeated if symptoms of hepatic injury occur.",
    "zh": "该患者的LDL水平严重升高。这种程度的高脂血症，特别是伴有冠心病家族史，提示家族性高胆固醇血症，并带来很高的心血管事件风险。HMG-CoA还原酶抑制剂（他汀类药物）是大多数高胆固醇血症患者的一线治疗药物，并已被证明可以降低心脏事件的风险。他汀类药物是HMG-CoA的结构类似物，并竞争性抑制HMG-CoA还原酶，该酶负责胆固醇合成的限速步骤。\n\n他汀类药物的严重副作用包括肌病和肝炎。虽然肝酶轻度升高很常见，但严重的肝损伤（天门冬氨酸转氨酶/丙氨酸转氨酶水平超过正常上限的3倍以上）仅在不到1%的患者中出现，如果停药通常是可逆的。建议在开始他汀类药物治疗前进行肝功能检查；否则，除非出现肝损伤症状（如疲劳、不适、厌食），否则无需常规监测。\n\n(选项A) 载脂蛋白B (Apo-B) 是一种存在于致动脉粥样硬化的脂蛋白颗粒中的结构蛋白。每个脂蛋白颗粒仅含一个Apo-B分子，因此测量Apo-B水平可以量化LDL颗粒计数。LDL颗粒计数增加的患者发生心血管事件的风险更高。但是，其测量在临床上的效用有限，在这种情况下不会改变治疗方案。\n\n(选项B) 他汀类药物不会引起任何显著的血液学毒性。\n\n(选项C) 脂蛋白脂酶缺乏可导致家族性高甘油三酯血症（杂合子缺乏症）和乳糜微粒血症（纯合子缺乏症）综合征。这些疾病表现为血清甘油三酯水平升高，但不会导致LDL水平升高。\n\n(选项E) 由于胆固醇是肾上腺皮质激素和性腺类固醇激素合成的前体，理论上，他汀类药物可引起性腺功能减退或肾上腺皮质功能减退。然而，在临床上，血清皮质醇或性腺类固醇水平没有显著改变，除非患者同时使用其他肾上腺酶抑制剂（如酮康唑、氨鲁米特）。\n\n(选项F) 他汀类药物没有显著的肾脏副作用。在极少数情况下，它们可引起横纹肌溶解症，可诱发急性肾衰竭；但是，这种情况比肝功能障碍发生的频率低，并且与肌痛和肌红蛋白尿有关。\n\n教学目标：\nHMG-CoA还原酶抑制剂（他汀类药物）的常见副作用包括肌肉和肝脏毒性。在开始治疗前应检查肝转氨酶，如果出现肝损伤症状，应重复检查。"
  },
  "summary": {
    "en": "This question tests knowledge of the side effects of statin medications and the importance of monitoring liver function tests before initiating statin therapy. Statins can cause hepatotoxicity, and liver function tests should be checked before starting statin therapy to establish a baseline and monitor for any liver injury.\n\nTo solve this question, recall the common side effects of statins, particularly liver toxicity. Recognize that liver function tests are essential to assess liver health before starting statin therapy and to monitor for any potential liver damage during treatment.",
    "zh": "此问题测试对他汀类药物副作用的了解以及在开始他汀类药物治疗前监测肝功能检查的重要性。他汀类药物可引起肝毒性，在开始他汀类药物治疗前应检查肝功能检查以建立基线，并监测是否有任何肝损伤。\n\n要解决这个问题，请回忆他汀类药物的常见副作用，特别是肝毒性。认识到肝功能检查对于在开始他汀类药物治疗前评估肝脏健康以及在治疗期间监测任何潜在的肝损伤至关重要。"
  },
  "tags": "Hypercholesterolemia; Statin therapy; Liver function tests; Hepatotoxicity; HMG-CoA reductase inhibitors; Cardiology; Internal medicine",
  "category": "CVS",
  "question_id": "780",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\CVS 23\\780",
  "extracted_at": "2025-11-05T12:16:44.719711",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T17:31:24.288767",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}